What is HC Wainwright’s Forecast for PVLA FY2026 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Stock analysts at HC Wainwright issued their FY2026 earnings per share estimates for Palvella Therapeutics in a research report issued on Friday, November 6th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($6.40) for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($6.36) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q4 2026 earnings at ($1.94) EPS, Q1 2027 earnings at ($2.22) EPS, Q2 2027 earnings at ($2.83) EPS, Q3 2027 earnings at ($3.42) EPS, Q4 2027 earnings at ($3.10) EPS, FY2027 earnings at ($11.57) EPS, FY2028 earnings at ($9.87) EPS, FY2029 earnings at ($4.28) EPS and FY2030 earnings at $6.30 EPS.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.08.

PVLA has been the subject of a number of other reports. Oppenheimer raised their price target on Palvella Therapeutics from $210.00 to $232.00 and gave the stock an “outperform” rating in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. William Blair began coverage on shares of Palvella Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating for the company. Raymond James Financial set a $226.00 target price on shares of Palvella Therapeutics in a report on Friday, October 16th. Finally, Canaccord Genuity Group lifted their price target on shares of Palvella Therapeutics from $232.00 to $243.00 and gave the stock a “buy” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Palvella Therapeutics has an average rating of “Buy” and a consensus target price of $213.85.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $174.08 on Tuesday. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -31.65 and a beta of -0.21. The stock has a 50 day moving average price of $143.02 and a 200-day moving average price of $128.52. Palvella Therapeutics has a one year low of $72.22 and a one year high of $179.95.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,313 shares of Palvella Therapeutics stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total transaction of $537,313.54. Following the completion of the sale, the chief operating officer directly owned 2,165 shares in the company, valued at approximately $269,715.70. This trade represents a 66.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher P. Kiritsy sold 313 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total transaction of $49,141.00. Following the sale, the director directly owned 250 shares of the company’s stock, valued at $39,250. This represents a 55.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,056 shares of company stock valued at $8,756,946 in the last quarter. 17.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV bought a new stake in Palvella Therapeutics during the 1st quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. bought a new position in Palvella Therapeutics in the 2nd quarter worth about $35,000. Sterling Capital Management LLC grew its stake in Palvella Therapeutics by 907.7% in the 3rd quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock worth $54,000 after acquiring an additional 354 shares in the last quarter. Archer Investment Corp purchased a new position in shares of Palvella Therapeutics during the second quarter worth approximately $69,000. Finally, Quantbot Technologies LP purchased a new position in shares of Palvella Therapeutics during the second quarter worth approximately $71,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Key Headlines Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $243 from $232 and maintained a Buy rating. The target implies substantial upside from the $174.08 reference price, although it is an analyst forecast, not a guarantee. Canaccord Genuity recommendations
• Positive Sentiment: HC Wainwright assigned Palvella a Strong-Buy rating and projects a longer-term earnings turnaround, forecasting positive EPS of $6.30 in 2030.
• Negative Sentiment: HC Wainwright expects continued losses in the intervening years, including a forecast loss of $11.57 per share for 2027, following estimated losses of $6.40 per share in 2026. These are analyst estimates, not company guidance.

About Palvella Therapeutics

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania.

Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Palvella is led by founder and Chief Executive Officer Wes Kaupinen.